Regulation of the THRA gene, encoding the thyroid hormone nuclear receptor TRα1, in intestinal lesions.
Fiche publication
Date publication
juillet 2022
Journal
Molecular oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Dr DOMON-DELL Claire, Dr FREUND Jean-Noël, Dr PLATEROTI Michelina
Tous les auteurs :
Giolito MV, La Rosa T, Farhat D, Bodoirat S, Guardia GDA, Domon-Dell C, Galante PAF, Freund JN, Plateroti M
Lien Pubmed
Résumé
The THRA gene, encoding the thyroid hormone nuclear receptor TRα1, is expressed in an increasing gradient at the bottom of intestinal crypts, overlapping with high Wnt and Notch activities. Importantly, THRA is upregulated in colorectal cancers, particularly in the high-Wnt molecular subtype. The basis of this specific and/or altered expression pattern has remained unknown. To define the mechanisms controlling THRA transcription and TRα1 expression, we used multiple in vitro and ex vivo approaches. Promoter analysis demonstrated that transcription factors important for crypt homeostasis and altered in colorectal cancers, such as transcription factor 7-like 2 (TCF7L2; Wnt pathway), recombining binding protein suppressor of hairless (RBPJ; Notch pathway), and homeobox protein CDX2 (epithelial cell identity), modulate THRA activity. Specifically, although TCF7L2 and CDX2 stimulated THRA, RBPJ induced its repression. In-depth analysis of the Wnt-dependent increase showed direct regulation of the THRA promoter in cells and of TRα1 expression in murine enteroids. Given our previous results on the control of the Wnt pathway by TRα1, our new results unveil a complex regulatory loop and synergy between these endocrine and epithelial-cell-intrinsic signals. Our work describes, for the first time, the regulation of the THRA gene in specific cell and tumor contexts.
Mots clés
THRA, TRα1, colon cancer, intestinal organoids, thyroid hormone nuclear receptor
Référence
Mol Oncol. 2022 07 31;: